Literature DB >> 10400713

Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

M Flint1, C Maidens, L D Loomis-Price, C Shotton, J Dubuisson, P Monk, A Higginbottom, S Levy, J A McKeating.   

Abstract

A truncated soluble form of the hepatitis C virus E2 glycoprotein, E2661, binds specifically to the surface of cells expressing human CD81 (hCD81) but not other members of the tetraspanin family (CD9, CD63, and CD151). No differences were noted between the level of E2661 binding to hCD81 expressed on the surface of rat RBL or KM3 cells compared to Daudi and Molt-4 cells, suggesting that additional human-cell-specific factors are not required for the primary interaction of E2 with the cell surface. E2 did not interact with African green monkey (AGM) CD81 on the surface of COS cells, which differs from the hCD81 sequence at four residues within the second extracellular region (EC2) (amino acids [aa] 163, 186, 188, and 196), suggesting that one or more of these residues defines the site of interaction with E2. Various recombinant forms of CD81 EC2 show differences in the ability to bind E2, suggesting that CD81 conformation is important for E2 recognition. Regions of E2 involved in the CD81 interaction were analyzed, and our data suggest that the binding site is of a conformational nature involving aa 480 to 493 and 544 to 551 within the E2 glycoprotein. Finally, we demonstrate that ligation of CD81 by E2661 induced aggregation of lymphoid cells and inhibited B-cell proliferation, demonstrating that E2 interaction with CD81 can modulate cell function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10400713      PMCID: PMC112700          DOI: 10.1128/JVI.73.8.6235-6244.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules.

Authors:  L E Bradbury; G S Kansas; S Levy; R L Evans; T F Tedder
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

2.  Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells.

Authors:  R R Spaete; D Alexander; M E Rugroden; Q L Choo; K Berger; K Crawford; C Kuo; S Leng; C Lee; R Ralston
Journal:  Virology       Date:  1992-06       Impact factor: 3.616

3.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

4.  Association between the pH-dependent conformational change of West Nile flavivirus E protein and virus-mediated membrane fusion.

Authors:  T Kimura; A Ohyama
Journal:  J Gen Virol       Date:  1988-06       Impact factor: 3.891

5.  TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen.

Authors:  S Takahashi; C Doss; S Levy; R Levy
Journal:  J Immunol       Date:  1990-10-01       Impact factor: 5.422

6.  Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J M Thomas; C M Maidens; C Shotton; S Levy; W S Barclay; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein.

Authors:  F Guirakhoo; R A Bolin; J T Roehrig
Journal:  Virology       Date:  1992-12       Impact factor: 3.616

8.  Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses.

Authors:  R Ralston; K Thudium; K Berger; C Kuo; B Gervase; J Hall; M Selby; G Kuo; M Houghton; Q L Choo
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  Antibodies to dengue 2 virus E-glycoprotein synthetic peptides identify antigenic conformation.

Authors:  J T Roehrig; A J Johnson; A R Hunt; R A Bolin; M C Chu
Journal:  Virology       Date:  1990-08       Impact factor: 3.616

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  206 in total

1.  Identification of a hepatic factor capable of supporting hepatitis C virus replication in a nonpermissive cell line.

Authors:  C T Yeh; H Y Lai; T C Chen; C M Chu; Y F Liaw
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells.

Authors:  Stéphanie Charrin; François Le Naour; Valérie Labas; Martine Billard; Jean-Pierre Le Caer; Jean-François Emile; Marie-Anne Petit; Claude Boucheix; Eric Rubinstein
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

3.  Direct binding of the ligand PSG17 to CD9 requires a CD9 site essential for sperm-egg fusion.

Authors:  Diego A Ellerman; Cam Ha; Paul Primakoff; Diana G Myles; Gabriela S Dveksler
Journal:  Mol Biol Cell       Date:  2003-10-03       Impact factor: 4.138

4.  Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81.

Authors:  Heidi E Drummer; Kirilee A Wilson; Pantelis Poumbourios
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Characterization of mice lacking the tetraspanin superfamily member CD151.

Authors:  Mark D Wright; Sean M Geary; Stephen Fitter; Gregory W Moseley; Lai-Man Lau; Kuo-Ching Sheng; Vasso Apostolopoulos; Edouard G Stanley; Denise E Jackson; Leonie K Ashman
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

6.  CD81-dependent binding of hepatitis C virus E1E2 heterodimers.

Authors:  Laurence Cocquerel; Chiung-Chi Kuo; Jean Dubuisson; Shoshana Levy
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

Review 8.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

Review 9.  Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.

Authors:  Mario U Mondelli; Antonella Cerino; Annalisa Meola; Alfredo Nicosia
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

10.  Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication.

Authors:  Lucie Goueslain; Khaled Alsaleh; Pauline Horellou; Philippe Roingeard; Véronique Descamps; Gilles Duverlie; Yann Ciczora; Czeslaw Wychowski; Jean Dubuisson; Yves Rouillé
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.